Drugs / 23-valent polysaccharide vaccine
last change Mar 2005 re-read 2 minutes ago

23-valent polysaccharide vaccine

Vaccine

Developed for
pneumococcal infection
Investigated by
Centers for Disease Control and Prevention · Emory University

Trials 1 · a red edge is where a trial was stopped

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00164411 Jan 2004 → Mar 2005 pneumococcal infection Centers for Disease Control and Prevention Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 23-valent polysaccharide vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00164411
Known as Pneumococcal Polysaccharide Vaccine Pneumococcal Polysaccharide Vaccine (23-valent)” NCT00164411
Known as PPV23 “The only vaccine licensed in the United States for protecting adults against pneumococcal disease (PPV23) protects against invasive disease in observational studies but has...” NCT00164411
Modality Vaccine “The only vaccine licensed in the United States for protecting adults against pneumococcal disease (PPV23) protects against invasive disease in observational studies but has...” NCT00164411